País: Canadá
Língua: inglês
Origem: Health Canada
MIGALASTAT (MIGALASTAT HYDROCHLORIDE)
AMICUS THERAPEUTICS CANADA INC.
A16AX14
MIGALASTAT
123MG
CAPSULE
MIGALASTAT (MIGALASTAT HYDROCHLORIDE) 123MG
ORAL
14
Prescription
OTHER MISCELLANEOUS THERAPEUTIC AGENTS
Active ingredient group (AIG) number: 0159450001; AHFS:
APPROVED
2017-09-05
_ _ _GALAFOLD® (migalastat capsules) _ _Page 1 of 47_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr GALAFOLD® Migalastat capsules Capsules, 123 mg migalastat (as migalastat hydrochloride), Oral Alpha-galactosidase A (alpha-Gal A) pharmacological chaperone Amicus Therapeutics Canada Inc. 100 King Street West, Suite 1600 1 First Canadian Place Toronto ON M5X 1G5 Canada Imported and Distributed by : Innomar Strategies 8030 Esquesing Line Milton, ON L9T 6W3 Date of Initial Authorization: SEP 05, 2017 Date of Revision: JUL 28, 2023 Submission Control Number: 276328 _ _ _GALAFOLD® (migalastat capsules) _ _Page 2 of 47_ RECENT MAJOR LABEL CHANGES 1 Indications, 1.1 Pediatrics 03/2023 4 Dosage and Administration 03/2023 7 Warnings and Precautions, 7.1.3 Pediatrics 03/2023 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 4 4.1 Dosing Considerations .............................................................................................. 4 4.2 Recommended Dose and Dosage Adjustment ......................................................... 5 4.4 Administration ... Leia o documento completo